Diverse Biotech Announces Its DBT-12733 Molecule Demonstrated to Be Up to 8,000 Times More Effective Than Temozolomide for Brain Cancer

On October 26, 2021 Diverse Biotech, Inc., View Source, reported that its DBT-12733 molecule was more effective in killing glioblastoma tumor cells than temozolomide (Temodar), outperforming all expectations in early testing (Press release, Diverse Biotech, OCT 26, 2021, View Source [SID1234591975]). In fact, DBT-12733 maintained its efficacy against the temozolomide-resistant glioblastoma cancer cell line T98G, with an 8,000-fold higher effect.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"T98G cells are actually resistant to temozolomide, due to a cellular change that results in limited treatment options for patients. DBT-12733 has shown to be most effective at killing cells with this particular alteration."

Tweet this
25 times (25x) more effective on A172 cells
50 times (50x) more effective on U87-MG cells
8,000 times (8,000x) more effective on T98G cells
Chief Science Officer, Philip Arlen, PhD, adds, "T98G cells are actually resistant to temozolomide, due to a cellular change that results in limited treatment options for patients. DBT-12733 has shown to be most effective at killing cells with this particular alteration."

Glioblastoma is very hard to treat. On May 4th, 2020, the FDA granted Diverse Biotech "Orphan Drug Status" for this investigational drug for the treatment of glioblastoma, and it continues to show significant promise against the disease.

Board Chairman William Fisher said, "I was pleasantly surprised with the results against T98G cells. We are increasingly having a better idea of the capabilities of what’s coming through our pipeline and the data is extraordinary. We are excited to get this new molecule over to our collaborators at The Preston Robert Tisch Brain Tumor Center at Duke University for further studies."